ArticleBMC gastroenterology2025
Human epidermal growth factor receptor 2 expression and socio-demographic, clinical, and histopathological characteristics in gastric carcinoma at St Francis Hospital Nsambya, Uganda.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence of HER2 overexpression in gastric adenocarcinoma and its clinicopathological correlation: a prospective study from Bir Hospital, Nepal.International journal of surgery open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGastric carcinoma is a significant global health burden with diverse clinicopathological features and molecular alterations influencing prognosis and treatment. Human epidermal growth factor receptor 2 (HER2) overexpression is a critical biomarker in gastric carcinoma, guiding targeted therapeutic interventions. This study aimed to assess HER2 expression and its association with clinicopathological characteristics of gastric carcinoma.
methodsA retrospective cross-sectional study was conducted using consecutive sampling to retrieve gastric carcinoma tissue blocks that met the inclusion criteria. A total of 136 formalin-fixed, paraffin-embedded tissue blocks from patients aged 18 years and above (2013-2023) at St. Francis Hospital Nsambya were analyzed. HER2 expression was evaluated using immunohistochemistry (IHC) with a standardized test kit. Associations between HER2 expression and demographic and histopathological characteristics were analyzed.
resultsAmong 136 patients, the mean age was 59.63 years, with 48.53% aged 48-67 years. Most were male (63.24%) and from the Central region (60.70%). The intestinal subtype was the most common (78.68%), with 52.21% of tumors poorly differentiated, and tumors predominantly located in the antrum (32.35%), cardia (30.15%), and body (24.26%). Regarding HER2 expression, 11.76% were positive (3+), 2.21% equivocal (2+), and 86.03% negative (0 or 1+). HER2 positivity was significantly associated with residence in the Western region (aPR = 3.67; 95% CI: 1.33-10.11; p = 0.02) and with mixed-type tumors (aPR = 3.00; 95% CI: 1.70-5.30; p < 0.001).
conclusionHER2 overexpression in gastric carcinoma was low. Nevertheless, the findings underscore the importance of routine HER2 testing and access to targeted therapy. Observed associations point to potential high-risk groups warranting further investigation in larger, multicenter studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.